In reaction of quinoline N-oxide with 2-aminopyridine in the presence of tosyl chloride the substrate undergoes reductive amination into 2-pyridyl(2-quinolyl)an-line, and with 3- and 4-aminopyridines reductive tosylamination occurs to furnish N-tosyl derivatives of the corresponding 3- and 4-pyridyl(2-quinolyl)amines. N-tosyl derivatives of aminopyridines also react along reductive tosylamination pathway.
In reaction of quinoline N-oxide with 2-aminopyridine in the presence of tosyl chloride the substrate undergoes reductive amination into 2-pyridyl(2-quinolyl)an-line, and with 3- and 4-aminopyridines reductive tosylamination occurs to furnish N-tosyl derivatives of the corresponding 3- and 4-pyridyl(2-quinolyl)amines. N-tosyl derivatives of aminopyridines also react along reductive tosylamination pathway.
Pyridinyl Amide Ion Pairs as Lewis Base Organocatalysts
作者:Julian Helberg、Torsten Ampßler、Hendrik Zipse
DOI:10.1021/acs.joc.0c00114
日期:2020.4.17
Pyridinyl amide ion pairs carrying various electron-withdrawing substituents were synthesized with selected ammonium or phosphonium counterions. Compared to neutral pyridine-based organocatalysts, these new ion pair Lewis bases display superior catalytic reactivity in the reaction of isocyanates with alcohols and the aza-Morita–Baylis–Hillman reaction of hindered electrophiles. The high catalytic activity
Reductive Acylamination of Pyridine N-Oxide with Aminopyridines and Their N-p-Tolylsulfonyl Derivatives
作者:M. A. Solekhova、Yu. V. Kurbatov
DOI:10.1007/s11178-005-0134-x
日期:2005.1
Pyridine N-oxide reacts with 2- and 3-aminopyridines and their N-p-tolylsulfonyl derivatives in alkaline medium in the presence of p-toluenesulfonyl chloride to give N-p-tolylsulfonyl-2,2′- and 2,3′-dipyridylamines, respectively, as a result of reductive acylamination. In the reactions with 4-aminopyridine and 4-p-tolylsulfonyl-aminopyridine, their N-p-tolylsulfonyl- and N,N-bis(p-tolylsulfonyl) derivatives are formed, while reductive acylamination does not occur.
6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.